Home / Healthcare/ AstraZeneca diabetes drug shows promise in heart failure

AstraZeneca diabetes drug shows promise in heart failure

Comments / {{hitsCtrl.values.hits}} Views / Thursday, 22 August 2019 00:00

Reuters: AstraZeneca made strides on Tuesday toward its goal of adding heart failure to the conditions that can be treated by its diabetes drug Farxiga, putting it ahead of a rival medicine from Eli Lilly.

The British drugmaker said Farxiga was successful in reducing the risk of deadly heart attacks or disease progression in patients with a common form of heart failure in a clinical trial that could help win regulatory approval for its wider use.

Farxiga, already one of AstraZeneca’s top 10 drugs by sales, met the main goal of the so-called DAPA-HF trial, which tested the medicine in addition to the standard treatment in patients whose heart cannot pump enough blood.

Farxiga is part of the SGLT2-inhibitor class of antidiabetics that cause the kidneys to expel blood sugar from the body through urine.

Rival treatments in the diabetes market include Eli Lilly and Boehringer Ingelheim, but they have yet to show a benefit for heart failure patients.

Around 40% of participants in the Farxiga trial suffered from type-2 diabetes, as is common among heart failure patients, while the rest did not. The results are welcome news for AstraZeneca after US regulators declined to approve Farxiga for use as a supplement to insulin in adults with type-1 diabetes where insulin alone was not able to control blood sugar levels.

Diabetes is associated with a high risk of heart failure.

Heart failure affects about 64 million people worldwide and half of patients die within five years of diagnosis, AstraZeneca said.

The company, which did not a publish peak sales estimate for the drug, said trial participants suffered from the HFrEF subtype of heart failure, accounting for about half of heart failure cases.

“This (the study results) will give the drug broad applicability and is strong validation of its utility, particularly in diabetics,” Liberum analysts said.

“The result will also reinforce Farxiga’s utility in diabetes at a time when oral GLP-1 might enter the market,” they added, referring to a rival group of drugs.

GLP-1 drugs imitate an intestinal hormone that stimulates the production of insulin. Danish insulin producer Novo Nordisk has already grabbed a chunk of the diabetes market with its GLP-1 drug Ozempic.

“The Dapa-HF study was seen as a ‘wild-card’ by the market, with a low probability of success, today being the first time a Phase III study has reported a heart failure benefit for an SGLT-2, in non-diabetic patients,” JP Morgan analysts said.

They added that peak sales potential for the indication could exceed $ 900 million.

AstraZeneca said it would present more details from the trial at a later stage and discuss results with drug regulators.


Share This Article

Facebook Twitter


1. All comments will be moderated by the Daily FT Web Editor.

2. Comments that are abusive, obscene, incendiary, defamatory or irrelevant will not be published.

3. We may remove hyperlinks within comments.

4. Kindly use a genuine email ID and provide your name.

5. Spamming the comments section under different user names may result in being blacklisted.


Today's Columnists

Forensic Audits part of bond scam cover-up

Saturday, 25 January 2020

From the time the bond scam was carried out by the Ranil Wickremesinghe administration, that administration under the guidance of the former Prime Minister had been avoiding the law by regularly bringing up various distractions so that the true natur

Halting mega projects is untimely; Govt. can explore other options

Friday, 24 January 2020

In a Sunday newspaper on 5 January a news item titled ‘Mega projects on hold until August budget,’ ‘Drop in revenue after tax reductions prevents spending on major constructions,’ was not a development-friendly headline. It may be accurate o

Is any further expenditure on the Port City a waste of money?

Friday, 24 January 2020

Erase from the mind all that you have read and heard about it. Then take a blank piece of paper, draw an irregular circle, and draw a line to divide it into two. On the bottom half write 300 acres. That is our Port City! To get the size into a proper

Foundations of incivility

Friday, 24 January 2020

The lack of advanced political consciousness and democratic discipline can be considered as one of the main reasons for the crisis and the failure that Sri Lanka is facing. This can be considered a situation that has prevailed since independence. Sri

Columnists More